Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


LAP-BAND Safe, Effective for Obese With BMI <40 kg/m²
Improvements in weight loss, quality of life, and comorbidities through two years

TUESDAY, May 7 (HealthDay News) -- The LAP-BAND adjustable gastric banding system (LAGB) is safe and effective for obese individuals with a body mass index (BMI) of 30 to 39.9 kg/m², according to a study published online May 2 in Obesity.

To examine the safety and effectiveness of the LAGB system for patients with a BMI of 30 to 39.9 kg/m², Robert Michaelson, from Northwest Weight Loss Surgery in Everett, Wash., and colleagues recruited 149 subjects (90.6 percent female; mean BMI, 35.3 kg/m²), who had failed prior weight loss attempts, from seven surgical centers.

The researchers found that, at one year, 84.6 percent of subjects achieved ≥30 percent excess weight loss (EWL), with a mean EWL of 65.0 percent. In addition, 66.4 percent of the participants were no longer obese (BMI, <30 kg/m²). For 64.4 percent of those with dyslipidemia, 59.6 percent with hypertension, and 85.7 percent with diabetes, improvements were seen in baseline comorbidities at one year. There was also significant improvement in quality-of-life (IWQOL-Lite), with the results from year-one maintained or improved at two years. Each additional 10 percent weight loss at year-two correlated with a 7.1 percent increase in IWQOL-Lite, and with decreases of 13.7 mg/dL in triglycerides; 3.5 mg/dL in fasting glucose; and 3.3 mm Hg in systolic blood pressure. Adverse events were generally mild to moderate and resolved within one month.

"LAGB is a safe and effective treatment option for obese people with a BMI of 30 to 39.9, with weight loss and comorbidity improvement through at least two years," the authors write.

Allergan, the maker of the Lap-Band, designed and funded the study and performed statistical analysis of the data. Several authors disclosed financial ties to Allergan.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)



Copyright © 2013 HealthDay. All rights reserved.

April 25, 2014

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

Physician Groups Find Fault With Medicare Payment Data Release

Out-of-Pocket Costs Decline for Patients With Diabetes CME

FDA Proposes E-Cigarette Regulations

Impact of Rising Incidence of Measles Discussed

FDA Approves Sylvant for Multicentric Castleman's Disease

Irrational Health Beliefs Predict Adherence to Cardiac Rehab CME